Proteasome inhibitor bortezomib for the treatment of multiple myelomaCAVO, M.Leukemia. 2006, Vol 20, Num 8, pp 1341-1352, issn 0887-6924, 12 p.Article

STAGING OF CHRONIC LYMPHOCYTIC LEUKEMIABACCARANI M; CAVO M; GOBBI M et al.1982; BLOOD; ISSN 0006-4971; USA; DA. 1982; VOL. 59; NO 6; PP. 1191-1196; BIBL. 26 REF.Article

Allogeneic bone marrow transplantation in multiple myelomaTURA, S; CAVO, M.Hematology/oncology clinics of North America. 1992, Vol 6, Num 2, pp 425-435, issn 0889-8588Article

PROGNOSTIC FACTORS AND SURVIVAL IN MULTIPLE MYELOMA. ANALYSIS OF 91 CASES TREATED BY MELPHALAN AND PREDNISONEGOBBI M; CAVO M; SAVELLI G et al.1980; HAEMOTOLOGICA (ROMA); ISSN 0390-6078; ITA; DA. 1980; VOL. 65; NO 4; PP. 437-445; ABS. ITA; BIBL. 20 REF.Article

Alpha-interferon improves survival and remission duration in P-190^BCR-ABL positive adult acute lymphoblastic leukemiaVISANI, G; MARTINELLI, G; PICCALUGA, P et al.Leukemia. 2000, Vol 14, Num 1, pp 22-27, issn 0887-6924Article

Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma : a case reportRONDELLI, D; BANDINI, G; CAVO, M et al.Bone marrow transplantation (Basingstoke). 1999, Vol 24, Num 6, pp 685-687, issn 0268-3369Article

Syngeneic transplantation in multiple myeloma: a case-matched comparison with autologous and allogeneic transplantationGAHRTON, G; SVENSSON, H; GUILHOT, F et al.Bone marrow transplantation (Basingstoke). 1999, Vol 24, Num 7, pp 741-745, issn 0268-3369Article

High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myelomaCAVO, M; BANDINI, G; MOTTA, M et al.Bone marrow transplantation (Basingstoke). 1998, Vol 22, Num 1, pp 27-32, issn 0268-3369Article

Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodiesTAZZARI, P. L; GOBBI, M; DINOTA, A et al.Clinical and experimental immunology (Print). 1987, Vol 70, Num 1, pp 192-200, issn 0009-9104Article

Ascorbic acid inhibits antitumor activity of bortezomib in vivoPERRONE, G; HIDESHIMA, T; BACCARANI, M et al.Leukemia. 2009, Vol 23, Num 9, pp 1679-1686, issn 0887-6924, 8 p.Article

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantationPALUMBO, A; SEZER, O; KUMAR, S et al.Leukemia. 2009, Vol 23, Num 10, pp 1716-1730, issn 0887-6924, 15 p.Article

Plasma cell P170 expression and response to treatment in multiple myelomaPATRIARCA, F; MELLI, C; DAMIANI, D et al.Haematologica (Roma). 1996, Vol 81, Num 3, pp 232-237, issn 0390-6078Article

Prognostic factors in allogeneic bone marrow transplantation for multiple myelomaGAHRTON, G; TURA, S; DE LAURENZI, A et al.Journal of clinical oncology. 1995, Vol 13, Num 6, pp 1312-1322, issn 0732-183XArticle

The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myelomaCAVO, M; BENNI, M; GOZZETTI, A et al.Baillière's clinical haematology. 1995, Vol 8, Num 4, pp 795-813, issn 0950-3536Article

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomasTURA, S; MAZZA, P; ZANCHINI, R et al.Cancer chemotherapy and pharmacology. 1989, Vol 23, Num 2, pp 123-125, issn 0344-5704Article

Bone marrow purging for multiple myeloma by avidin-biotin immunoadsorptionLEMOLI, R. M; GOBBI, M; TAZZARI, P. L et al.Transplantation. 1989, Vol 47, Num 2, pp 385-387, issn 0041-1337Article

Improvement of human myeloma stem cell growth in a liquid culture system supplemented with phytohemagglutininVISANI, G; LEMOLI, R. M; DINOTA, A et al.International journal of cell cloning. 1988, Vol 6, Num 5, pp 313-323, issn 0737-1454Article

SECONDARY CUTANEOUS PLASMACYTOMA = PLASMOCYTOME CUTANE SECONDAIRECAVO M; GOBBI M; GHETTI P et al.1983; ACTA HAEMATOLOGICA; ISSN 0001-5792; CHE; DA. 1983; VOL. 69; NO 4; PP. 287-288; BIBL. 6 REF.Article

Autologous Transplantation and Maintenance Therapy in Multiple MyelomaPALUMBO, A; CAVALLO, F; GENUARDI, M et al.The New England journal of medicine. 2014, Vol 371, Num 10, pp 895-905, issn 0028-4793, 11 p.Article

Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition diseaseBRIOLI, A; ZAMAGNI, E; CAVO, M et al.Bone marrow transplantation (Basingstoke). 2012, Vol 47, Num 9, pp 1248-1249, issn 0268-3369, 2 p.Article

Solitary plasmacytoma of bone and extramedullary plasmacytoma : two different entities ?GALIENI, P; CAVO, M; AVVISATI, G et al.Annals of oncology. 1995, Vol 6, Num 7, pp 687-691, issn 0923-7534Article

Evidence for increased intracellular transport of m-sarcolysine (alkylating moiety) when combined with two amino acid analogs (PTT-119)VERLICCHI, F; BOSCHI, S; VISANI, G et al.Blut. 1990, Vol 61, Num 5, pp 311-313, issn 0006-5242, 3 p.Article

Allogeneic bone marrow transplantation for multiple myelomaTURA, S; CAVO, M; ROSTI, G et al.Bone marrow transplantation (Basingstoke). 1989, Vol 4, pp 106-108, issn 0268-3369, 3 p., suppl. 4Conference Paper

Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myelomaGOBBI, M; CAVO, M; BOLOGNESI, A et al.European journal of haematology. Supplementum. 1989, Vol 51, pp 176-181, issn 0902-4506, 6 p.Conference Paper

High-dose chemoradiotherapy and allogeneic bone marrow transplantation in multiple myelomaTURA, S; CAVO, M; GOBBI, M et al.European journal of haematology. Supplementum. 1989, Vol 51, pp 191-195, issn 0902-4506, 5 p.Conference Paper